These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

845 related items for PubMed ID: 27645238

  • 21. Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors.
    Weber J, Rose JD, Vazquez AC, Winner D, Margot N, McColl DJ, Miller MD, Quiñones-Mateu ME.
    PLoS One; 2013; 8(6):e65631. PubMed ID: 23776513
    [Abstract] [Full Text] [Related]

  • 22. Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase Inhibitors.
    Zhang WW, Cheung PK, Oliveira N, Robbins MA, Harrigan PR, Shahid A.
    J Infect Dis; 2018 Oct 20; 218(11):1773-1776. PubMed ID: 30010985
    [Abstract] [Full Text] [Related]

  • 23. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness.
    Wares M, Mesplède T, Quashie PK, Osman N, Han Y, Wainberg MA.
    Retrovirology; 2014 Jan 17; 11():7. PubMed ID: 24433497
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.
    Hassounah SA, Liu Y, Quashie PK, Oliveira M, Moisi D, Brenner BG, Sandstrom PA, Mesplède T, Wainberg MA.
    J Virol; 2015 Dec 17; 89(23):12002-13. PubMed ID: 26378179
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
    Heger E, Theis AA, Remmel K, Walter H, Pironti A, Knops E, Di Cristanziano V, Jensen B, Esser S, Kaiser R, Lübke N.
    J Virol Methods; 2016 Dec 17; 238():29-37. PubMed ID: 27737783
    [Abstract] [Full Text] [Related]

  • 28. The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.
    Xiao MA, Cleyle J, Yoo S, Forrest M, Krullaars Z, Pham HT, Mesplède T.
    Antimicrob Agents Chemother; 2023 May 17; 67(5):e0138622. PubMed ID: 37071019
    [Abstract] [Full Text] [Related]

  • 29. HIV drug resistance against strand transfer integrase inhibitors.
    Anstett K, Brenner B, Mesplede T, Wainberg MA.
    Retrovirology; 2017 Jun 05; 14(1):36. PubMed ID: 28583191
    [Abstract] [Full Text] [Related]

  • 30. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
    Modica S, Rossetti B, Lombardi F, Lagi F, Maffeo M, D'Autilia R, Pecorari M, Vicenti I, Bruzzone B, Magnani G, Paolucci S, Francisci D, Penco G, Sacchini D, Zazzi M, De Luca A, Di Biagio A.
    HIV Med; 2019 Feb 05; 20(2):137-146. PubMed ID: 30461149
    [Abstract] [Full Text] [Related]

  • 31. Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance.
    Richetta C, Tu NQ, Delelis O.
    Viruses; 2022 Nov 22; 14(12):. PubMed ID: 36560595
    [Abstract] [Full Text] [Related]

  • 32. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.
    Yoshinaga T, Kobayashi M, Seki T, Miki S, Wakasa-Morimoto C, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T.
    Antimicrob Agents Chemother; 2015 Jan 22; 59(1):397-406. PubMed ID: 25367908
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.
    Mesplède T, Osman N, Wares M, Quashie PK, Hassounah S, Anstett K, Han Y, Singhroy DN, Wainberg MA.
    J Antimicrob Chemother; 2014 Oct 22; 69(10):2733-40. PubMed ID: 24917583
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.
    Quashie PK, Mesplède T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA.
    J Virol; 2012 Mar 22; 86(5):2696-705. PubMed ID: 22205735
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.
    Quashie PK, Mesplède T, Han YS, Veres T, Osman N, Hassounah S, Sloan RD, Xu HT, Wainberg MA.
    Antimicrob Agents Chemother; 2013 Dec 22; 57(12):6223-35. PubMed ID: 24080645
    [Abstract] [Full Text] [Related]

  • 39. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
    Nguyen HL, Ruxrungtham K, Delaugerre C.
    Intervirology; 2012 Dec 22; 55(4):287-95. PubMed ID: 22456540
    [Abstract] [Full Text] [Related]

  • 40. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.
    Cheung PK, Shahid A, Dong W, Lepik KJ, Montaner JSG, Brockman MA, Brumme ZL, Brumme CJ.
    J Antimicrob Chemother; 2022 Mar 31; 77(4):979-988. PubMed ID: 35061879
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.